KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Accumulated Expenses (2016 - 2018)

NovoCure's Accumulated Expenses history spans 5 years, with the latest figure at $16.7 million for Q4 2018.

  • For Q4 2018, Accumulated Expenses rose 25.85% year-over-year to $16.7 million; the TTM value through Dec 2018 reached $16.7 million, up 25.85%, while the annual FY2018 figure was $16.7 million, 25.85% up from the prior year.
  • Accumulated Expenses for Q4 2018 was $16.7 million at NovoCure, up from $13.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $16.7 million in Q4 2018 and bottomed at $5.8 million in Q4 2014.
  • The 5-year median for Accumulated Expenses is $8.3 million (2015), against an average of $10.3 million.
  • The largest annual shift saw Accumulated Expenses decreased 8.68% in 2016 before it skyrocketed 76.14% in 2017.
  • A 5-year view of Accumulated Expenses shows it stood at $5.8 million in 2014, then skyrocketed by 41.26% to $8.3 million in 2015, then fell by 8.68% to $7.5 million in 2016, then surged by 76.14% to $13.3 million in 2017, then grew by 25.85% to $16.7 million in 2018.
  • Per Business Quant, the three most recent readings for NVCR's Accumulated Expenses are $16.7 million (Q4 2018), $13.3 million (Q4 2017), and $7.5 million (Q4 2016).